Bristol-Myers' Celgene Deal Can Still Be a Winner -- Heard on the Street
June 24 2019 - 12:19PM
Dow Jones News
By Charley Grant
Bad news at Bristol-Myers Squibb comes with a significant silver
lining.
Less than three months after beating back shareholder opposition
to its proposed acquisition of Celgene, the pharmaceuticals giant
faces another obstacle in closing the $74 billion deal: It said
Monday that it plans to sell Celgene's psoriasis drug Otezla to
satisfy concerns of antitrust regulators.
As a result, the company now expects the deal to close by the
end of this year or early in 2020, several months behind the
original schedule.
Bristol-Myers had forecast $45 billion in free cash flow for the
combined company over the first three years after the deal closes.
That forecast is now headed lower, since analysts expect annual
Otezla sales to top $2 billion by 2020, according to FactSet.
To make matters worse, the company separately unveiled
disappointing data for its lead cancer drug in the treatment of
liver disease.
The company's shares fell 7% in morning trading.
That disappointment is a real one, but Bristol-Myers is still in
position to bounce back. Otezla is a proven blockbuster drug in a
growing market. It should continue to generate cash for a while,
since Otezla's key patents don't expire until 2028. There will
likely be significant interest from either rival drug companies or
from private equity. Since industry growth rates are low and
capital is abundant, it wouldn't be surprising for Otezla to fetch
$10 billion or more in a sale.
Even after taxes on the sale, those proceeds will significantly
reduce debt on Bristol-Myers' balance sheet, which was slated to
top $50 billion when the deal closes.
And Bristol-Myers hasn't closed the door on this market
altogether. The company is currently enrolling patients for
late-stage trials of its own next-generation psoriasis drug.
Monday's share-price sickness shouldn't linger for long.
Write to Charley Grant at charles.grant@wsj.com
(END) Dow Jones Newswires
June 24, 2019 12:04 ET (16:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024